应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
IOVA Iovance Biotherapeutics, Inc.
交易中 02-05 15:33:07 EST
2.37
-0.07
-3.07%
最高
2.46
最低
2.25
成交量
1,378万
今开
2.38
昨收
2.44
日振幅
8.61%
总市值
9.39亿
流通市值
7.19亿
总股本
3.97亿
成交额
3,238万
换手率
4.53%
流通股本
3.04亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Iovance Biotherapeutics, Inc.盘中异动 早盘急速拉升5.33%
市场透视 · 2025-12-17
Iovance Biotherapeutics, Inc.盘中异动 早盘急速拉升5.33%
Iovance Biotherapeutics Inc:Iov-Lun-202试验将于2026年推进,针对非鳞状非小细胞肺癌的Lifileucel BLA
美股速递 · 2025-11-03
Iovance Biotherapeutics Inc:Iov-Lun-202试验将于2026年推进,针对非鳞状非小细胞肺癌的Lifileucel BLA
Iovance Biotherapeutics公布潜在最佳临床数据,针对晚期非小细胞肺癌的Lifileucel Til细胞治疗
美股速递 · 2025-11-03
Iovance Biotherapeutics公布潜在最佳临床数据,针对晚期非小细胞肺癌的Lifileucel Til细胞治疗
Iovance Biotherapeutics, Inc.盘中异动 早盘股价大涨5.00%
市场透视 · 2025-09-05
Iovance Biotherapeutics, Inc.盘中异动 早盘股价大涨5.00%
Iovance Biotherapeutics, Inc.盘中异动 大幅拉升5.12%
市场透视 · 2025-08-22
Iovance Biotherapeutics, Inc.盘中异动 大幅拉升5.12%
异动解读 | Iovance Biotherapeutics盘前大涨27.20%,获加拿大卫生部Amtagvi合规通知
异动解读 · 2025-08-19
异动解读 | Iovance Biotherapeutics盘前大涨27.20%,获加拿大卫生部Amtagvi合规通知
异动解读 | Iovance Biotherapeutics盘前大涨27.20%,获加拿大卫生部Amtagvi合规通知
异动解读 · 2025-08-19
异动解读 | Iovance Biotherapeutics盘前大涨27.20%,获加拿大卫生部Amtagvi合规通知
盘前异动|英特尔涨超6%,AEye涨超15%,Iovance飙升20%,Palo Alto Networks绩后涨超5%
老虎资讯综合 · 2025-08-19
盘前异动|英特尔涨超6%,AEye涨超15%,Iovance飙升20%,Palo Alto Networks绩后涨超5%
美股夜盘 | AEye 涨超16%,Iovance Biotherapeutics涨超14%,Palo Alto Networks绩后涨近5%
老虎资讯综合 · 2025-08-19
美股夜盘 | AEye 涨超16%,Iovance Biotherapeutics涨超14%,Palo Alto Networks绩后涨近5%
英特尔美股夜盘涨超5%与软银签署20亿美元投资协议;AEye涨近17%与黑芝麻科技签署战略合作协议;IOVA涨超14%获
智通财经 · 2025-08-19
英特尔美股夜盘涨超5%与软银签署20亿美元投资协议;AEye涨近17%与黑芝麻科技签署战略合作协议;IOVA涨超14%获
Iovance Biotherapeutics, Inc.2024财年实现净利润-3.72亿美元,同比增加16.22%
市场透视 · 2025-03-08
Iovance Biotherapeutics, Inc.2024财年实现净利润-3.72亿美元,同比增加16.22%
Iovance Biotherapeutics, Inc.盘中异动 下午盘股价大涨5.03%报4.12美元
市场透视 · 2025-03-06
Iovance Biotherapeutics, Inc.盘中异动 下午盘股价大涨5.03%报4.12美元
Iovance Biotherapeutics, Inc.盘中异动 股价大跌5.07%报3.84美元
市场透视 · 2025-03-04
Iovance Biotherapeutics, Inc.盘中异动 股价大跌5.07%报3.84美元
异动解读 | Iovance Biotherapeutics股价盘中暴跌27.66%,分析师下调目标价引发担忧
异动解读 · 2025-02-28
异动解读 | Iovance Biotherapeutics股价盘中暴跌27.66%,分析师下调目标价引发担忧
异动解读 | Iovance Biotherapeutics (IOVA)盘前暴跌26.24%,安银下调目标价或为主因
异动解读 · 2025-02-28
异动解读 | Iovance Biotherapeutics (IOVA)盘前暴跌26.24%,安银下调目标价或为主因
Baird:维持Iovance Biotherapeutics(IOVA.US)评级,由优于大市调整至优于大市评级, 目标价由24.00美元调整至20.00美元。
金融界 · 2025-02-28
Baird:维持Iovance Biotherapeutics(IOVA.US)评级,由优于大市调整至优于大市评级, 目标价由24.00美元调整至20.00美元。
Iovance Biotherapeutics(IOVA.US):2024年Q4财报实现营收7369.4万美元,前值为48.2万美元,预期值为7217万美元;每股收益为-0.26美元,前值为-0.45美元,预期值为-0.27美元。
金融界 · 2025-02-28
Iovance Biotherapeutics(IOVA.US):2024年Q4财报实现营收7369.4万美元,前值为48.2万美元,预期值为7217万美元;每股收益为-0.26美元,前值为-0.45美元,预期值为-0.27美元。
Iovance Biotherapeutics 2024年第四季度GAAP每股亏损$(0.26)好于预期$(0.27),销售额$7370万好于预期$7239.3万
财报速递 · 2025-02-28
Iovance Biotherapeutics 2024年第四季度GAAP每股亏损$(0.26)好于预期$(0.27),销售额$7370万好于预期$7239.3万
Iovance Biotherapeutics, Inc.盘中异动 股价大涨5.05%报5.62美元
市场透视 · 2025-02-27
Iovance Biotherapeutics, Inc.盘中异动 股价大涨5.05%报5.62美元
Iovance Biotherapeutics, Inc.盘中异动 大幅下跌5.02%报5.49美元
市场透视 · 2025-02-24
Iovance Biotherapeutics, Inc.盘中异动 大幅下跌5.02%报5.49美元
加载更多
公司概况
公司名称:
Iovance Biotherapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司,专注于培养细胞,使用自体肿瘤浸润淋巴细胞(TIL)治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。该公司于2007年9月17日在内华达州成立。
发行价格:
--
{"stockData":{"symbol":"IOVA","market":"US","secType":"STK","nameCN":"Iovance Biotherapeutics, Inc.","latestPrice":2.365,"timestamp":1770323581976,"preClose":2.44,"halted":0,"volume":13776808,"delay":0,"changeRate":-0.03073770491803268,"floatShares":304000000,"shares":396967970,"eps":-1.19871,"marketStatus":"交易中","change":-0.075,"latestTime":"02-05 15:33:07 EST","open":2.38,"high":2.46,"low":2.25,"amount":32376413.580051202,"amplitude":0.086066,"askPrice":2.37,"askSize":11985,"bidPrice":2.36,"bidSize":3363,"shortable":3,"etf":0,"ttmEps":-1.19871,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770325200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.44,"preHourTrading":{"tag":"盘前","latestPrice":2.41,"preClose":2.44,"latestTime":"09:29 EST","volume":86219,"amount":209665.3380535,"timestamp":1770301792034,"change":-0.03,"changeRate":-0.012295,"amplitude":0.036885},"postHourTrading":{"tag":"盘后","latestPrice":2.45,"preClose":2.44,"latestTime":"19:59 EST","volume":147388,"amount":360668.111,"timestamp":1770253190950,"change":0.01,"changeRate":0.004098,"amplitude":0.012295},"volumeRatio":1.389596,"impliedVol":0.9934,"impliedVolPercentile":0.498},"requestUrl":"/m/hq/s/IOVA","defaultTab":"news","newsList":[{"id":"2592269917","title":"Iovance Biotherapeutics, Inc.盘中异动 早盘急速拉升5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592269917","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592269917?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:31","pubTimestamp":1765981873,"startTime":"0","endTime":"0","summary":"北京时间2025年12月17日22时31分,Iovance Biotherapeutics, Inc.股票出现波动,股价快速上涨5.33%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.27%。Iovance Biotherapeutics, Inc.公司简介:Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司,通过利用人体免疫系统识别和摧毁多种癌细胞的能力,为每位患者提供个性化治疗,开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217223113a6ae704b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217223113a6ae704b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"gpt_icon":0},{"id":"1151227716","title":"Iovance Biotherapeutics Inc:Iov-Lun-202试验将于2026年推进,针对非鳞状非小细胞肺癌的Lifileucel BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=1151227716","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151227716?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:10","pubTimestamp":1762171809,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics Inc:Iov-Lun-202试验将于2026年推进,针对非鳞状非小细胞肺癌的Lifileucel BLA","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"1166982075","title":"Iovance Biotherapeutics公布潜在最佳临床数据,针对晚期非小细胞肺癌的Lifileucel Til细胞治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1166982075","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166982075?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:01","pubTimestamp":1762171277,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公布潜在最佳临床数据,针对晚期非小细胞肺癌的Lifileucel Til细胞治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"2565519409","title":"Iovance Biotherapeutics, Inc.盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565519409","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565519409?lang=zh_cn&edition=full","pubTime":"2025-09-05 21:50","pubTimestamp":1757080200,"startTime":"0","endTime":"0","summary":"北京时间2025年09月05日21时50分,Iovance Biotherapeutics, Inc.股票出现波动,股价大幅拉升5.00%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.88%。Iovance Biotherapeutics, Inc.公司简介:Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司,通过利用人体免疫系统识别和摧毁多种癌细胞的能力,为每位患者提供个性化治疗,开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905215000a4b677fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905215000a4b677fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"2561402577","title":"Iovance Biotherapeutics, Inc.盘中异动 大幅拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561402577","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561402577?lang=zh_cn&edition=full","pubTime":"2025-08-22 22:00","pubTimestamp":1755871243,"startTime":"0","endTime":"0","summary":"北京时间2025年08月22日22时00分,Iovance Biotherapeutics, Inc.股票出现波动,股价快速拉升5.12%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.18%。Iovance Biotherapeutics, Inc.公司简介:Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司,通过利用人体免疫系统识别和摧毁多种癌细胞的能力,为每位患者提供个性化治疗,开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082222004494f4cf61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082222004494f4cf61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"1177990075","title":"异动解读 | Iovance Biotherapeutics盘前大涨27.20%,获加拿大卫生部Amtagvi合规通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1177990075","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177990075?lang=zh_cn&edition=full","pubTime":"2025-08-19 16:38","pubTimestamp":1755592704,"startTime":"0","endTime":"0","summary":"周二盘前,生物技术公司Iovance Biotherapeutics股价大幅上涨27.20%,引起市场广泛关注。消息面上,Iovance Biotherapeutics获得了加拿大卫生部对其产品Amtagvi的合规通知。Amtagvi是Iovance Biotherapeutics的重点产品之一,这次获得加拿大卫生部的合规通知,不仅提升了公司的市场地位,也增强了投资者对公司未来发展前景的信心。分析人士认为,这一利好消息可能会对公司的长期业绩产生积极影响,因此引发了市场的强烈反应。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"gpt_icon":0},{"id":"1125630895","title":"异动解读 | Iovance Biotherapeutics盘前大涨27.20%,获加拿大卫生部Amtagvi合规通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1125630895","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125630895?lang=zh_cn&edition=full","pubTime":"2025-08-19 16:38","pubTimestamp":1755592702,"startTime":"0","endTime":"0","summary":"生物技术公司Iovance Biotherapeutics今日盘前大涨27.20%,引起投资者广泛关注。该股价的强劲上涨反映了市场对公司最新进展的积极反应。据悉,Iovance Biotherapeutics股价大涨的主要原因是公司获得了加拿大卫生部对其产品Amtagvi的合规通知。Amtagvi是Iovance Biotherapeutics的一款重要产品,这一合规通知的获得不仅提升了投资者对公司产品线的信心,也增强了市场对公司未来发展前景的预期。然而,投资者仍需密切关注公司后续在加拿大市场的具体进展,以及Amtagvi的商业化潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"gpt_icon":0},{"id":"1177106527","title":"盘前异动|英特尔涨超6%,AEye涨超15%,Iovance飙升20%,Palo Alto Networks绩后涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177106527","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177106527?lang=zh_cn&edition=full","pubTime":"2025-08-19 16:06","pubTimestamp":1755590790,"startTime":"0","endTime":"0","summary":"$英特尔$盘前涨超6%,$软银集团$与$英特尔$签署20亿美元投资协议,软银将以每股23美元的价格购买英特尔普通股;$AEye$盘前涨超15%,与$黑芝麻$科技签署战略合作协议;$Iovance Biotherapeutics$盘前涨超20%,获加拿大卫生部对Amtagvi的合规通知;网络安全巨头$Palo Alto Networks$盘前涨超5%,Q4营收25.4亿美元,高于市场预期的25亿美元;$小赢科技$盘前涨超9%,$Q2$营收大增65.6%。","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"216ce9b8dee407746c2471036318398e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4579","IE00BMPRXN33.USD","BK4550","IOVA","LU2023250504.SGD","BK4598","LU1989764664.SGD","BK4605","LU2355687059.USD","IE00BMPRXR70.SGD","LU1917777945.USD","BK4588","IE00B19Z9505.USD","LU1720051108.HKD","INTC","LU2023250843.SGD","LU1720051017.SGD","LU2148611432.USD","PANW","LU0348723411.USD","BK4515"],"gpt_icon":0},{"id":"1139212650","title":"美股夜盘 | AEye 涨超16%,Iovance Biotherapeutics涨超14%,Palo Alto Networks绩后涨近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139212650","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139212650?lang=zh_cn&edition=full","pubTime":"2025-08-19 08:18","pubTimestamp":1755562720,"startTime":"0","endTime":"0","summary":"美东8月18日,美股夜盘,$英特尔(INTC)$涨超5%,与软银签署20亿美元投资协议;AEye 涨超16%,与$黑芝麻(000716)$科技签署战略合作协议;$Iovance Biotherapeutics(IOVA)$涨超14%,获加拿大卫生部对Amtagvi的合规通知;网络安全巨头$Palo Alto Networks(PANW)$绩后涨近5%,Q4营收25.4亿美元,高于市场预期的25亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4526b843d40f390bebf97cd36114a0ab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861215975.USD","INTC","LU0234570918.USD","LU1861220033.SGD","IOVA","LU2286300806.USD","IE00B19Z8W00.USD","LU2106854487.HKD","BK4598","BK4527","BK4560","BK4097","LU1623119135.USD","BK4554","PANW","BK4532","LU2125909759.SGD","LU2543165471.USD","BK4581","LU2125909916.SGD"],"gpt_icon":0},{"id":"2560132816","title":"英特尔美股夜盘涨超5%与软银签署20亿美元投资协议;AEye涨近17%与黑芝麻科技签署战略合作协议;IOVA涨超14%获","url":"https://stock-news.laohu8.com/highlight/detail?id=2560132816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560132816?lang=zh_cn&edition=full","pubTime":"2025-08-19 08:12","pubTimestamp":1755562339,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e1762a1fd1464e223bc235648bd9e526","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4515","IE00BMPRXN33.USD","LU1720051108.HKD","INTC","LU2023250504.SGD","BK4550","LU2023250843.SGD","IE00B19Z9505.USD","LU2125909759.SGD","BK4141","BK4602","LU0321505868.SGD","LU0321505439.SGD","BK0226","IE00B19Z8X17.USD","IOVA","LU2357305700.SGD","LU1861215975.USD","LU0348723411.USD","LU1917777945.USD","LU1548497426.USD","LU1923622291.USD","BK4581","BK4097","LU1169590202.USD","BK4534","BK4554","BK4512","BK4575","LU1861220033.SGD","LU2286300806.USD","BK4588","LU2265009873.SGD","BK4535","LU2543165471.USD","BK4560","BK4598","LU2106854487.HKD","BK4527","000716","LU0234570918.USD","BK4605","BK4139","LU1974910355.USD","BK4579","LU1169589451.USD","BK4529","BK4612","PANW","LU2355687059.USD"],"gpt_icon":0},{"id":"2517189430","title":"Iovance Biotherapeutics, Inc.2024财年实现净利润-3.72亿美元,同比增加16.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517189430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517189430?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363251,"startTime":"0","endTime":"0","summary":"3月8日,Iovance Biotherapeutics, Inc.公布财报,公告显示公司2024财年净利润为-3.72亿美元,同比增加16.22%;其中营业收入为1.64亿美元,同比增加13681.51%,每股基本收益为-1.28美元。从资产负债表来看,Iovance Biotherapeutics, Inc.总负债2.00亿美元,其中短期债务12.90百万美元,资产负债比为4.55,流动比率为3.75。机构评级:截至2025年3月8日,当前有13家机构对Iovance Biotherapeutics, Inc.目标价做出预测,其中目标均价为20.54美元,其中最低目标价为6.00美元,最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000219a2647f65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000219a2647f65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA"],"gpt_icon":0},{"id":"2517237539","title":"Iovance Biotherapeutics, Inc.盘中异动 下午盘股价大涨5.03%报4.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517237539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517237539?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:22","pubTimestamp":1741202536,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日03时22分,Iovance Biotherapeutics, Inc.股票出现波动,股价快速上涨5.03%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中,整体涨幅为2.06%。Iovance Biotherapeutics, Inc.公司简介:Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司,通过利用人体免疫系统识别和摧毁多种癌细胞的能力,为每位患者提供个性化治疗,开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306032216963b1b32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306032216963b1b32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"gpt_icon":0},{"id":"2516677687","title":"Iovance Biotherapeutics, Inc.盘中异动 股价大跌5.07%报3.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677687","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677687?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:39","pubTimestamp":1741099151,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时39分,Iovance Biotherapeutics, Inc.股票出现波动,股价急速跳水5.07%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.12%。Iovance Biotherapeutics, Inc.公司简介:Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司,通过利用人体免疫系统识别和摧毁多种癌细胞的能力,为每位患者提供个性化治疗,开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223912989bae64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223912989bae64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"gpt_icon":0},{"id":"1152554288","title":"异动解读 | Iovance Biotherapeutics股价盘中暴跌27.66%,分析师下调目标价引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1152554288","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152554288?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:43","pubTimestamp":1740753780,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics(IOVA.US)周五股价盘中大跌27.66%,引发广泛关注。\n\n导致股价暴跌的主要原因是,Baird分析师下调了IOVA的目标股价。Baird维持IOVA的优于大市评级不变,但将其目标价从24美元下调至20美元。\n\n分析师下调目标价反映出外界对该公司前景的担忧。作为一家细胞疗法生物科技公司,Iovance Biotherapeutics致力于开发创新的癌症免疫疗法产品。分析师对公司后续药品管线以及销售增长潜力的预期可能较暗淡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"gpt_icon":0},{"id":"1186787959","title":"异动解读 | Iovance Biotherapeutics (IOVA)盘前暴跌26.24%,安银下调目标价或为主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1186787959","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186787959?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:34","pubTimestamp":1740753296,"startTime":"0","endTime":"0","summary":"生物科技公司Iovance Biotherapeutics (IOVA.US)今日盘前股价大跌26.24%,引发市场关注。\n\n消息面上,资深投行Baird周四晚间下调了IOVA的目标价,由24美元下调至20美元,或许是导致这一盘前暴跌的主要原因。\n\n尽管Baird仍然维持IOVA \"优于大市\"的投资评级不变,但下调目标价反映了分析师对该公司未来业绩预期的担忧。IOVA目前正在开发针对多种癌症的临床晚期新型免疫疗法,处于重要阶段,后续的数据和监管审批结果将决定公司前景。而目标价下调无疑在一定程度上打击了投资者的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Iovance Biotherapeutics (IOVA)盘前暴跌26.24%,安银下调目标价或为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"gpt_icon":0},{"id":"2514278327","title":"Baird:维持Iovance Biotherapeutics(IOVA.US)评级,由优于大市调整至优于大市评级, 目标价由24.00美元调整至20.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514278327","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514278327?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:28","pubTimestamp":1740752883,"startTime":"0","endTime":"0","summary":"Baird:维持Iovance Biotherapeutics(IOVA.US)评级,由优于大市调整至优于大市评级, 目标价由24.00美元调整至20.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28222848467015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IOVA"],"gpt_icon":0},{"id":"2514535563","title":"Iovance Biotherapeutics(IOVA.US):2024年Q4财报实现营收7369.4万美元,前值为48.2万美元,预期值为7217万美元;每股收益为-0.26美元,前值为-0.45美元,预期值为-0.27美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514535563","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514535563?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:21","pubTimestamp":1740691300,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics(IOVA.US):2024年Q4财报实现营收7369.4万美元,前值为48.2万美元,预期值为7217万美元;每股收益为-0.26美元,前值为-0.45美元,预期值为-0.27美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28052148442324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IOVA"],"gpt_icon":0},{"id":"1127368942","title":"Iovance Biotherapeutics 2024年第四季度GAAP每股亏损$(0.26)好于预期$(0.27),销售额$7370万好于预期$7239.3万","url":"https://stock-news.laohu8.com/highlight/detail?id=1127368942","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127368942?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:10","pubTimestamp":1740690649,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics 报告称,季度每股亏损$,好于分析师一致预期的$,增幅为3.7%。这比去年同期的$每股亏损增加了42.22%。这比去年同期的$482.000千销售额增加了15.19千百分比。以上内容来自Benzinga Earnings专栏,原文如下:Iovance Biotherapeutics reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 3.7 percent. This is a 42.22 percent increase over losses of $ per share from the same period last year. The company reported quarterly sales of $73.700 million which beat the analyst consensus estimate of $72.393 million by 1.81 percent. T","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance Biotherapeutics 2024年第四季度GAAP每股亏损$(0.26)好于预期$(0.27),销售额$7370万好于预期$7239.3万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"gpt_icon":1},{"id":"2514438576","title":"Iovance Biotherapeutics, Inc.盘中异动 股价大涨5.05%报5.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514438576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514438576?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:36","pubTimestamp":1740666970,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时36分,Iovance Biotherapeutics, Inc.股票出现异动,股价大幅拉升5.05%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.79%。Iovance Biotherapeutics, Inc.公司简介:Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司,通过利用人体免疫系统识别和摧毁多种癌细胞的能力,为每位患者提供个性化治疗,开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223610a2567b39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223610a2567b39&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"gpt_icon":0},{"id":"2514377582","title":"Iovance Biotherapeutics, Inc.盘中异动 大幅下跌5.02%报5.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514377582","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514377582?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:53","pubTimestamp":1740412426,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时53分,Iovance Biotherapeutics, Inc.股票出现波动,股价急速跳水5.02%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.12%。Iovance Biotherapeutics, Inc.公司简介:Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司,通过利用人体免疫系统识别和摧毁多种癌细胞的能力,为每位患者提供个性化治疗,开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235346962eabce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235346962eabce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.iovance.com","stockEarnings":[{"period":"1week","weight":-0.1127},{"period":"1month","weight":-0.0041},{"period":"3month","weight":0.0563},{"period":"6month","weight":0.1564},{"period":"1year","weight":-0.58},{"period":"ytd","weight":-0.1062}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司,专注于培养细胞,使用自体肿瘤浸润淋巴细胞(TIL)治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。该公司于2007年9月17日在内华达州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.029113},{"month":2,"riseRate":0.454545,"avgChangeRate":0.107771},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.04457},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.013596},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.091207},{"month":6,"riseRate":0.454545,"avgChangeRate":0.1436},{"month":7,"riseRate":0.727273,"avgChangeRate":0.047009},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.000211},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.078972},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.022017},{"month":11,"riseRate":0.727273,"avgChangeRate":0.07065},{"month":12,"riseRate":0.636364,"avgChangeRate":0.051779}],"exchange":"NASDAQ","name":"Iovance Biotherapeutics, Inc.","nameEN":"Iovance Biotherapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Iovance Biotherapeutics, Inc.,IOVA,Iovance Biotherapeutics, Inc.股票,Iovance Biotherapeutics, Inc.股票老虎,Iovance Biotherapeutics, Inc.股票老虎国际,Iovance Biotherapeutics, Inc.行情,Iovance Biotherapeutics, Inc.股票行情,Iovance Biotherapeutics, Inc.股价,Iovance Biotherapeutics, Inc.股市,Iovance Biotherapeutics, Inc.股票价格,Iovance Biotherapeutics, Inc.股票交易,Iovance Biotherapeutics, Inc.股票购买,Iovance Biotherapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}